Description
Interceptor Spectrum Tasty Chews for Dogs 2-8 Lbs (Up to 4 Kg) is a monthly oral chewable tablet combining milbemycin oxime and praziquantel for broad-spectrum internal parasite prevention and control. Each tablet in this variant delivers 2.3 mg milbemycin oxime and 22.8 mg praziquantel, calibrated for dogs weighing between 2 and 8 lbs (up to approximately 4 kg). The product is approved for use in puppies and dogs from six weeks of age onwards.
Recommended for
Dogs and puppies weighing 2 to 8 lbs (up to 4 kg) from 6 weeks of age.
Indication/Coverage
For dogs suffering from, or at risk from, mixed parasitic infections, Interceptor Spectrum Tasty Chews addresses the following indications:
- Heartworm prevention: Prevention of heartworm disease caused by Dirofilaria immitis (larval stages, administered monthly to interrupt larval development before adult establishment).
- Roundworm treatment: Treatment and control of adult Toxocara canis and Toxascaris leonina
- Hookworm treatment: Treatment and control of adult Ancylostoma caninum
- Whipworm treatment: Treatment and control of adult Trichuris vulpis
- Tapeworm treatment: Treatment and control of adult tapeworm infections caused by Taenia pisiformis, Echinococcus multilocularis, and Echinococcus granulosus.
Key Benefits
The following clinical properties distinguish this formulation across the parasite types it targets.
- Early-age eligibility: Labeled for use from six weeks of age and 2 lbs body weight, covering the window when puppies are most vulnerable to gastrointestinal parasite burdens before broader weight-band products become applicable.
- Dual active compounds: The combination of milbemycin oxime (a macrocyclic lactone) and praziquantel (a pyrazinoisoquinoline) allows a single monthly tablet to address both nematode and cestode infections simultaneously, rather than requiring separate dewormers.
- Systemic nematode clearance: Milbemycin oxime acts systemically, disrupting glutamate-gated chloride ion channels in invertebrate nerve and muscle cells to eliminate roundworm, hookworm, and whipworm infections at the adult stage.
- Tapeworm efficacy: Praziquantel causes tegumental disruption and increased permeability in tapeworm cells, leading to paralysis and expulsion of adult Taenia pisiformis, multilocularis, and E. granulosus.
- Heartworm prevention confirmed: In controlled laboratory studies, six consecutive monthly doses achieved 100% effectiveness against experimentally induced immitis infection in dogs.
- Chewable palatability: In a field acceptability study involving 115 client-owned dogs, 108 of 115 dogs accepted the chewable from the owner’s hand without requiring placement in a bowl or mouth, reducing the administration burden for small-breed dogs that resist tablet pilling.
- Once-monthly dosing schedule: A single chewable administered once every 30 days maintains heartworm prevention coverage and suppresses gastrointestinal parasite reestablishment across the full treatment cycle.
Caution
Hazards to Humans
Not for human use. Keep out of reach of children. Wash hands thoroughly after handling the chewable tablet. Avoid contact with eyes. Do not store near food or animal feed.
Hazards to Domestic Animals
For oral administration only. This variant is labeled for dogs and puppies weighing 2 to 8 lbs (up to 4 kg) from six weeks of age. Do not administer to dogs below 2 lbs or younger than six weeks. Use with caution in debilitated, aged, pregnant, or nursing animals, and consult a veterinarian prior to administration in these cases. Individual sensitivity to milbemycin oxime or praziquantel may occur in rare instances. Consult a veterinarian before concurrent use with other antiparasitic agents or medications that may interact with macrocyclic lactones.
Possible Side Effects
Monitor your dog in the hours following each monthly administration. Adverse reactions at the labeled dose were not reported in field or laboratory studies; however, overdose safety studies identified the following dose-dependent signs.
- Gastrointestinal reactions: Vomiting occurred in some dogs across multiple safety studies; one dog in the field acceptability trial vomited immediately after accepting the chewable. Soft feces and diarrhea were also noted, with similar incidence across treatment and control groups at standard dosing.
- Neurological signs (at supratherapeutic doses): Ataxia, decreased activity, salivation, and tremors were observed in safety studies at 3 and 5 times the maximum label dose. These signs appeared within the first 24 hours post-dosing and resolved spontaneously. At the labeled 1x dose, one instance of ataxia was recorded in a single animal across the puppy safety cohort.
- Systemic signs: One dog in a tapeworm efficacy study exhibited abnormal leaning behavior within 24 hours of treatment at the standard dose. This finding was isolated and not reproduced across other study cohorts.
If any of these signs appear after administration at the labeled dose, contact a veterinarian promptly.










Reviews
There are no reviews yet